Absci Corporation ABSI
8.18 USD +0.60 (+7.92%)
Regular-session close
8.42 +0.24 +2.93%
After hours · Nov 18, 7:43 PM ET
7.60 Day range 8.73
2.24 52-week range 12.55
- YTD
- +134.38%
- 1 year
- +188.03%
News
benzinga.com Guggenheim Maintains Buy on Absci, Lowers Price Target to $14 Guggenheim analyst Vamil Divan maintains Absci (NASDAQ:ABSI) with a Buy and lowers the price target from $15 to $14.
seekingalpha.com Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript Absci Corporation (ABSI) Q3 2026 Earnings Call Transcript
marketbeat.com Absci Q3 Earnings Call Highlights Absci NASDAQ: ABSI expects to release interim data from its experimental pattern hair loss treatment in December, followed by a fuller assessment in early 2027, executives said during the company's…
zacks.com Absci Corporation (ABSI) Reports Q3 Loss, Misses Revenue Estimates Absci Corporation (ABSI) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.2 per share a year ago.
benzinga.com Absci Q3 2026 Earnings Call Transcript Absci (NASDAQ:ABSI) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Absci Q3 EPS $(0.19) Beats $(0.20) Estimate, Sales $304.000K Miss $727.125K Estimate Absci (NASDAQ:ABSI) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 5 percent increase over losses of $(0.20) per share…
globenewswire.com Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results ABS-201™ HEADLINE™ trial progressing on track; 13-week interim proof-of-concept data for pattern hair loss (PHL) anticipated next month
globenewswire.com Absci Appoints Gerry Muhle as Chief Commercial Officer to Build Category-Defining Brands for ABS-201 and Its Broader Pipeline Global commercial executive brings a track record of launching prescription biologics and building consumer-driven brands at Galderma, Allergan and GSK Global commercial executive brings a track…
seekingalpha.com Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Absci Corporation (ABSI) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcriptbenzinga.com Jefferies Initiates Coverage On Absci with Buy Rating, Announces Price Target of $14 Jefferies analyst Andrew Tsai initiates coverage on Absci (NASDAQ:ABSI) with a Buy rating and announces Price Target of $14.
globenewswire.com Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with…
globenewswire.com Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026 VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with…
defenseworld.net Critical Contrast: Absci (NASDAQ:ABSI) and Black Diamond Therapeutics (NASDAQ:BDTX) Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare…
globenewswire.com Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial…
defenseworld.net Absci (NASDAQ:ABSI) vs. Silence Therapeutics (NASDAQ:SLN) Head to Head Contrast Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two…
defenseworld.net Contrasting Absci (NASDAQ:ABSI) & Valneva (NASDAQ:VALN) Valneva (NASDAQ: VALN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based…
seekingalpha.com Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
seekingalpha.com Absci: Positive Ph1 Data ABS-201 AGA And Several Catalysts Inbound (Upgrade) Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing…
defenseworld.net Absci Corporation $ABSI Shares Bought by Bank of America Corp DE Bank of America Corp DE raised its holdings in Absci Corporation (NASDAQ: ABSI) by 55.2% in the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 487,193 shares…
globenewswire.com Absci to Participate in Upcoming Investor Conferences VANCOUVER, Wash. and NEW YORK, Sept.
247wallst.com AMD's $1.3 Billion Portfolio Reveals Its Biggest Investments and Where AI Demand Lands Next On August 14, 2026, Advanced Micro Devices (NASDAQ:AMD | AMD Price Prediction) filed its first-ever 13F, pulling back the curtain on a $1.31 billion equity portfolio concentrated in just six…
zacks.com 4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines.
seekingalpha.com Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript Absci Corporation (ABSI) Q2 2026 Earnings Call Transcript
marketbeat.com Absci Q2 Earnings Call Highlights Absci NASDAQ: ABSI outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,…
